🔍
Search Results - clinical+and+disease+specializations+%3e+oncology+%3e+medulloblastoma
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Genetic Alterations in Medulloblastomas - MLL Genes as Targets for Diagnosis and Therapeutics
Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations,...
Published: 3/12/2026
|
Inventor(s):
Xiaosong Zhang
,
Hai Yan
,
Gregory Riggins
,
Victor Velculescu
,
Kenneth Kinzler
,
Darell Bigner
,
Nickolas Papadopoulos
,
Donald Parsons
,
Sian Jones
,
Rebecca Leary
,
Meng Li
,
Bert Vogelstein
Keywords(s):
Biomarker
,
Brain Cancer
,
Cancers
,
Clinical Diagnostics
,
Diagnostic Biomarker
,
Disease Indication
,
In Vitro Diagnostics
,
Medulloblastoma
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Neurology
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Diagnostics > Diagnostic Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Oncology > Brain Cancer
,
Clinical and Disease Specializations > Oncology > Medulloblastoma
Long Noncoding RNAs as Therapeutic and Diagnostic Markers for Childhood Cancer Medulloblastoma
Unmet NeedMedulloblastoma (MB) is the most common pediatric brain tumor and requires aggressive therapy in high-risk cases. MB is frequently resistant to treatment and is associated with high morbidity and mortality in affected individuals. There are four distinct molecular subgroups of MB (WNT, SHH, Group 3, and Group 4), which are characterized by...
Published: 3/13/2026
|
Inventor(s):
Ranjan Perera
,
Keisuke Katsushima
Keywords(s):
Biomarker
,
Cancers
,
Clinical Diagnostics
,
CNS and Neurological Disorders
,
Disease Indication
,
In Vitro Diagnostics (Old)
,
Novel
,
Predicted Novelty
,
Target
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations > Oncology > Medulloblastoma
,
Clinical and Disease Specializations > Rare Diseases
,
Technology Classifications > Diagnostics > Diagnostic Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum